Provided by Tiger Trade Technology Pte. Ltd.

Warrior Met Coal LLC

106.76
+0.03000.03%
Volume:355.32K
Turnover:38.50M
Market Cap:5.61B
PE:25.66
High:111.20
Open:107.63
Low:106.76
Close:106.73
52wk High:111.20
52wk Low:54.66
Shares:52.57M
Float Shares:51.78M
Volume Ratio:0.84
T/O Rate:0.69%
Dividend:0.32
Dividend Rate:0.30%
EPS(TTM):4.16
EPS(LYR):1.08
ROE:10.04%
ROA:5.17%
PB:2.45
PE(LYR):98.85

Loading ...

Warrior Met Coal is Maintained at Buy by UBS

Dow Jones
·
Jul 01

UBS Adjusts Price Target on Warrior Met Coal to $100 From $102, Maintains Buy Rating

MT Newswires Live
·
Jun 30

UBS Keeps Their Buy Rating on Warrior Met Coal (HCC)

TIPRANKS
·
Jun 30

Can-Fite Secures Japanese Patent Allowance for Namodenoson's Anti-Obesity Technology

GlobeNewswire
·
Jun 26

HENLIUS Announces First US Patient Dosed in Global Phase 1 Trial for HLX13, an Ipilimumab Biosimilar, in First-Line Unresectable Advanced Liver Cancer

Stock News
·
Jun 25

SQM Stock And 2 Global Exporters For Investors Looking Beyond Tech

Simply Wall St.
·
Jun 24

Warrior Met Coal’s (HCC) Insider Sales Amid Rich Valuation: What Do They Signal About Risk‑Reward?

Simply Wall St.
·
Jun 24

Can-Fite Publishes Peer-Reviewed Scientific Article Demonstrating the Broad Therapeutic Potential of Piclidenoson and Namodenoson

GlobeNewswire
·
Jun 22

Can-Fite to Present Late-Stage Clinical Pipeline and Licensing Opportunities at BIO International Convention 2026

GlobeNewswire
·
Jun 17

Warrior Met Coal Is Maintained at Buy by B. Riley Securities

Dow Jones
·
Jun 11

Warrior Met Coal Inc : B. Riley Raises Target Price to $123 From $117

THOMSON REUTERS
·
Jun 10

B. Riley Raises Price Target on Warrior Met Coal to $123 From $117, Keeps Buy Rating

MT Newswires Live
·
Jun 10

Warrior Met Coal Chief Administrative Officer Kelli K. Gant sells 20,000 shares for $2.2 million

Reuters
·
Jun 05

RBC Capital Reaffirms Their Hold Rating on Warrior Met Coal (HCC)

TIPRANKS
·
Jun 04

ABBISKO-B Presents Innovative Modeling Framework for ABSK-011 in HCC at PAGE Conference

Stock News
·
Jun 04

Chinese Coal-Mine Disruptions Could Be Major Supply Shock for Global Markets -- Market Talk

Dow Jones
·
May 28

Junshi Biosciences Announces Primary Endpoints Met in Final Analysis of Phase 3 Study for Perioperative Toripalimab plus Chemotherapy for Resectable Stage II-III NSCLC

GlobeNewswire
·
May 27

Assessing Warrior Met Coal (HCC) Valuation After Recent Share Price Softness And Blue Creek Growth Plans

Simply Wall St.
·
May 27

Junshi Biosciences Announces Approval of Toripalimab NDA for the 1st-line treatment of HER2 Expressing Urothelial Carcinoma

GlobeNewswire
·
May 21

Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson’s Potential in the Multi-Billion Dollar Canine Osteoarthritis Market

GlobeNewswire
·
May 18